This is not a direct comparison since populations differ, but it underscores that PT-141 might not replace PDE5is as the first choice for everyone
Peptides/Peptidomimetics: a Feasible Strategy for FXS Treatment All the strategies mentioned so far target different pathways, whose uncontrolled activity seems to be crucial in the pathology of FXS, but also in other neurological disorders and types of cancer (108, 109), leading to pleiotropic effects
However, clinical benefits are conferred after at least three years [13,14,15]
These medications work by triggering areas in the brain associated with satiety, effectively reducing our desire to overeat
We've compiled a short list of the most common pitfalls researchers encounter
the other half occur in new lesions